J. Mandel

发表

A Multi-Marker Genetic Association Test Based on the Rasch Model Applied to Alzheimer’s Disease

D. Commenges, I. Chumakov, Daniel Cohen, 2015, PloS one.

Whole-genome profiling helps to classify phyllodes tumours of the breast

P. Terrier, F. Reyal, P. Hupé, 2016, Journal of Clinical Pathology.

Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.

Serguei Nabirotchkin, R. Hajj, Daniel Cohen, 2022, Journal of Alzheimer's disease : JAD.

Full manuscript with supplementary data

Laura Bossi, Philippe Lehert, Serguei Nabirotchkin, 2015 .

EMA - A R package for Easy Microarray data analysis

Emmanuel Barillot, Nicolas Servant, Philippe Hupé, 2010, BMC Research Notes.

EMA-Easy Microarray data Analysis

P. Gestraud, E. Barillot, B. Asselain, 2010 .

Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy

K. Nave, I. Chumakov, Esther Graudens, 2014, Orphanet Journal of Rare Diseases.

An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

I. Chumakov, J. Pouget, Serguei Nabirotchkin, 2014, Orphanet Journal of Rare Diseases.

Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

I. Chumakov, J. Pouget, Serguei Nabirotchkin, 2016, Orphanet Journal of Rare Diseases.

A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment

I. Chumakov, Daniel Cohen, J. Micallef, 2015, Orphanet Journal of Rare Diseases.

A Comparison of Six Methods for Missing Data Imputation

Mickael Guedj, P Schmitt, J el, 2015 .